1. Bone marrow stem cells modified with human interleukin 10 attenuate acute rejection in rat lung allotransplantation.
- Author
-
Pieróg J, Tamo L, Fakin R, Kocher G, Gugger M, Grodzki T, Geiser T, Gazdhar A, and Schmid RA
- Subjects
- Acute Disease, Animals, Bone Marrow Cells immunology, Combined Modality Therapy, Enzyme-Linked Immunosorbent Assay, Humans, Male, Random Allocation, Rats, Rats, Inbred F344, Transplantation, Homologous, Treatment Outcome, Cyclosporine therapeutic use, Graft Rejection prevention & control, Immunosuppressive Agents therapeutic use, Interleukin-10 therapeutic use, Lung Transplantation, Mesenchymal Stem Cell Transplantation methods
- Abstract
Objectives: The aim of this study was to investigate new therapeutic options to attenuate acute rejection in a rat lung allograft model. Cell-based gene therapies have recently been reported as a novel curative option in acute and chronic diseases for which conventional treatments are not available. We studied the effect of human interleukin 10 (hIL-10) on expressing bone marrow-derived mesenchymal stem cells (BMSCs) in combination with cyclosporine A (CsA) on acute rejection of lung allografts in the rat., Methods: Lung allotransplantation was performed from male Brown Norway donor to male Fisher (F344) rats. Rat BMSCs were transfected with hIL-10 in vitro and introduced in the graft prior to implantation. Group A (n = 5) received CsA intraperitoneally (2.5 mg/kg body weight) for 5 days post-transplant; Group B (n = 5) received BMSC and CsA and Group C (n = 5) received hIL-10-BMSC before implantation and CsA. Graft function was assessed by blood gas levels only from the graft on day 5; tissue was sampled for histological grading of rejection and measurement of the wet-to-dry ratio., Results: All Group A control animals showed severe signs of rejection. On Day 5, all grafts in Group C showed improved gas exchange (mean arterial partial pressure of oxygen 222.2 ± 40.38 mmHg vs 92.36 ± 20.92 mmHg in Group B and 42.72 ± 18.07 mmHg in Group A). Histological examination revealed moderate-to-severe rejection in all animals in Group A [International Society for Heart and Lung Transplantation Level III B (ISHLT)] in contrast to low-to-moderate rejection in Group B (II-IIIA) and much improved histological grade in Group C (I-IIA). Moreover, the wet-to-dry ratio was also reduced in Group C (4.8 ± 1.19 compared with 4.78 ± 0.62 in Group B and 9.36 ± 0.90 in Group A)., Conclusions: The hIL-10 BMSC represent a promising novel method for localized cell-based gene therapy for acute rejection in a rat lung allograft model., (© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF